AGTC Genomics Expands Precision Medicine Footprint in East Malaysia with Integrated Genomics Portfolio Including PRS, Pharmacogenomics, Precision Oncology, Liquid Biopsy, and MCED

Mar 20
2 min read

AGTC Genomics continues to accelerate its national growth strategy with a successful Continuing Medical Education (CME) session at Jesselton Medical Centre, Kota Kinabalu, showcasing a comprehensive, end-to-end precision medicine ecosystem spanning preventive genomics, pharmacogenomics, and precision oncology.

The session reinforced AGTC Genomics’ positioning as a regional leader in integrated genomic healthcare, highlighting its full-stack capabilities across:

Polygenic Risk Score (PRS) for disease risk prediction
Pharmacogenomics (PGx) for optimized drug response
Comprehensive Gene Profiling (CGP) for precision oncology
Liquid Biopsy for non-invasive cancer detection and monitoring
Multi-Cancer Early Detection (MCED) for population-scale screening

A Shift Toward Early Detection and Prevention

Many diseases, particularly cancer, are often diagnosed at late stages when treatment becomes more complex. Early detection remains one of the most critical factors in improving survival outcomes and quality of life.

A doctor at the CME session shared:

“We are increasingly seeing that patients who are diagnosed earlier have significantly more treatment options and better outcomes. The challenge is awareness—many people still wait until symptoms appear.”

This reflects broader clinical evidence that early detection can significantly improve survival rates and reduce the need for aggressive treatments.

Building a Scalable, Multi-Revenue Precision Healthcare Model

AGTC Genomics presented a four-pillar clinical and commercial framework, designed to drive adoption across hospitals, specialists, and preventive health programs:

1. Risk Stratification (PRS) — Preventive Healthcare at Scale

Enables early identification of high-risk individuals for major non-communicable diseases
Supports expansion into corporate screening, insurance-linked genomics, and wellness programs
Drives long-term patient engagement and recurring preventive care

2. Pharmacogenomics (PGx) — Precision Prescribing

Reduces adverse drug reactions and improves therapeutic efficacy
Applicable across oncology, cardiology, psychiatry, and chronic disease management
Represents a high-margin, repeatable clinical testing segment

3. Precision Oncology (CGP & Liquid Biopsy) — High-Value Clinical Diagnostics

Comprehensive Gene Profiling (CGP) enables identification of actionable mutations for targeted therapy selection
Liquid biopsy (ctDNA-based testing) allows for non-invasive tumor profiling, treatment monitoring, and minimal residual disease (MRD) detection
Strong alignment with global oncology guidelines (NCCN, ESMO) and increasing clinical adoption

4. Multi-Cancer Early Detection (MCED) — Transformational Screening Opportunity

Single blood test capable of detecting multiple cancer types at early stages
Scalable for population-level screening programs
Supports healthcare cost reduction through earlier intervention

Expanding Access to Advanced Healthcare in Sabah

AGTC Genomics’ presence in Kota Kinabalu reflects its commitment to making advanced genomic testing more accessible across Malaysia, including East Malaysia.

Through education and collaboration with healthcare providers, AGTC Genomics aims to:

Increase awareness of early screening and prevention
Support doctors with advanced diagnostic tools
Empower individuals to take control of their health

Enquiries

Members of the public and healthcare professionals who wish to learn more about these services or future educational sessions are encouraged to contact Jesselton Medical Centre directly for further information.

About AGTC Genomics

AGTC Genomics is a leading precision medicine company in Malaysia, providing advanced genomic solutions across preventive health, pharmacogenomics, and oncology. Its portfolio includes CancerRiskDx, CancerScreenDx (MCED), OncoDx (CGP), LiquidDx, and CancerTRACE MRD, enabling clinicians to deliver predictive, preventive, and precision-driven care.